Market Overview

The Europe molecular diagnostics market was valued at USD 5.6 Billion in 2025 and is projected to reach USD 8.7 Billion by 2034. It is forecasted to grow at a compound annual growth rate (CAGR) of 5.04% during the period from 2026 to 2034. The market growth is propelled by an aging population, increased prevalence of infectious diseases and cancer, and greater adoption of precision medicine approaches, alongside advancements in diagnostic technologies and expanding testing infrastructure.

Study Assumption Years

  • Base Year: 2025
  • Historical Period: 2020-2025
  • Forecast Period: 2026-2034

Europe Molecular Diagnostics Market Key Takeaways

  • The Europe molecular diagnostics market size was valued at USD 5.6 Billion in 2025 with a CAGR of 5.04% forecasted for 2026 to 2034.
  • Products: Reagents and kits dominate with a 55% market share in 2025.
  • Technologies: Polymerase chain reactions (PCR) lead the market with a 38% share in 2025.
  • Application: Infectious diseases diagnostics represent the largest segment with a 46% share in 2025.
  • End User: Hospitals dominate the market with a 42% share in 2025.
  • The market is driven by rising disease burden, adoption of precision medicine, and innovations in genomic and PCR-based technologies.

Sample Request Link: https://www.imarcgroup.com/europe-molecular-diagnostics-market/requestsample

Market Growth Factors

Growing Geriatric Population

The continued growth of molecular diagnostics has been supported by the rapid ageing of the European population, with the proportion of the EU population over 65 estimated to be 21․6% on 1 January 2024․ The elderly are at higher risk of infectious disease and have a greater incidence of cancer and chronic illnesses, and healthcare systems are integrating molecular diagnostics into primary care, geriatric and chronic disease management․

Rising Prevalence of Infectious and Chronic Diseases

Increased incidences of viral infections, antimicrobial resistant infections, cancer, and genetic disorders has led to higher demand for fast and accurate diagnostic tests․ In 2025, the MVZ HPH Institute based in Hamburg launched HPH MRD, a tumor informed ctDNA blood test for the detection of minimal residual disease in solid tumors․ Molecular diagnostics provide the potential for early diagnosis to precisely recognize pathogens and enable healthcare systems to manage complex burdens of disease․

Increasing Healthcare Expenditure and Infrastructure Development

Meaningful investment in laboratory infrastructure and diagnostic capacity across Europe, improved by funding for equipment, workforce development and investment in research, will see more laboratories adopting high-precision automated molecular testing platforms․ For example, in 2024 The Royal Marsden NHS Foundation Trust opened the UK first genome testing lab using robotics to double the throughput of cancer testing․ This enables the pace of innovation and sustains market growth․

Market Segmentation

Product:

  • Reagents and Kits: Leading the market with 55% share in 2025, these consumables are vital for PCR, sequencing, and nucleic acid amplification workflows. Their recurring usage across clinical applications such as oncology screening and respiratory testing supports continuous revenue and market dominance.
  • Instruments
  • Software and Services

Technology:

  • Polymerase Chain Reactions (PCR): With a 38% market share in 2025, PCR is widely used for infectious disease detection and cancer diagnostics due to its accuracy, rapid turnaround, and advancements such as multiplex and digital PCR.
  • Hybridization
  • DNA Sequencing
  • Microarray
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Others

Application:

  • Infectious Diseases Diagnostics: The largest segment holding 46% share in 2025, driven by demands for rapid pathogen detection, antimicrobial resistance surveillance, and syndromic multiplex panel deployment.
  • Oncology
  • Genetic Testing
  • Blood Screening
  • Others

End User:

  • Hospitals: Holding 42% share in 2025, hospitals lead due to integration of molecular testing in emergency, oncology, and transplant care units and adoption of point-of-care platforms.
  • Laboratories
  • Others

Regional Insights

Germany holds a crucial position in the Europe molecular diagnostics market due to its advanced healthcare infrastructure, strong diagnostic industry presence, and high adoption of PCR and sequencing technologies. France, the United Kingdom, Italy, Spain, and other countries such as the Netherlands, Sweden, Switzerland, and Belgium also contribute significantly due to government support, expanding laboratory networks, and focus on personalized medicine. The regional growth is supported by investments in healthcare modernization and diagnostic capabilities across both public and private sectors.

Recent Developments & News

In December 2025, Seegene announced establishing a new subsidiary in France to strengthen its European presence and local support, targeting STI, gastrointestinal, and respiratory infection testing markets. The subsidiary will facilitate rollout of Seegene’s CURECA™ and STAgora™ platforms across Europe. In July 2025, SYSTAAQ Diagnostic Products received CE Mark certification for HBV and HCV molecular diagnostic tests, enabling marketing of real-time PCR kits for early detection and quantitation of viral loads across Europe and CE-recognizing regions.

Key Players

  • Seegene
  • SYSTAAQ Diagnostic Products

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.